Altered MT1 and MT2 melatonin receptors expression in the hippocampus of pilocarpine-induced epileptic rats.
Epilepsy & behavior : E&B
June 1, 2017
Anna Karynna Alves de Alencar Rocha et al. (6 authors)
Journal ArticleHuman Study
Extracted Claims (6)
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
melatonin | decrease | sleep disturbances | patients with epilepsy-related complications | - | alleviates | #1 |
melatonin | decrease | circadian alterations | patients with epilepsy-related complications | - | alleviates | #2 |
melatonin | decrease | seizures | - | - | attenuates | #3 |
melatonin in combination with AEDs | decrease | seizures | - | - | attenuates | #4 |
seizures | neutral | circadian system | - | - | cause changes | #5 |
seizures | neutral | melatonin production | - | - | cause changes | #6 |
Abstract
Clinical and experimental findings show that melatonin may be used as an adjuvant to the treatment of epilepsy-related complications by alleviates sleep disturbances, circadian alterations and attenuates seizures alone or in combination with AEDs. In addition, it has been observed that there is a circadian component on seizures, which cause changes in circadian system and in melatonin production. Nevertheless, the dynamic changes of the melatoninergic system, especially with regard to its membrane receptors (MT
Medical Subject Headings (MeSH)
AnimalsEpilepsyGene ExpressionHippocampusMalePilocarpineRatsRats, WistarReceptor, Melatonin, MT1Receptor, Melatonin, MT2
Study Links
PubMed ID28460319
Related Supplements